After the capital increase, the pharmaceutical start-up keeps on growing: the company has recruited two specialists in clinical essays and has moved to larger premises.
The start-up of Sophia Antipolis NicOx, a pharmaceutical company that exploits the properties of the nitric oxide to strengthen the action of already known medicines, grows again. The company has just announced the nomination of Dr Marco Sardina at the position of senior medical manager and of Dr Romano Rivolta at the position of Chemistry and formulation manager. These two positions are linked to Dr Giancarlo Santus, the vice-president in charge of the development.
Dr Sardina, 42, has 15 years of experience in clinical research. He is holder of doctorate in clinical pharmacology from the University of Padua and he was medical manager at Italfarmaco. Dr Rivolta, 37, a doctor in pharmacy from the University of Milan, was in charge of technology transfer at Patheon Italy. "Both of them bring us their great experience in the pharmaceutical industry and particularly in clinical essays and development",Michele Garufi, the CEO of NicOx, has declared.
As well, NicOx has moved. The start-up, after the capital increase of May 2001, has well developed (see the article "NicOx : the most important fund raising from a start-up on the French Riviera"). The company has left the World Trade Center in Sophia where it was pretty small to set up in larger premises of the Espace Gaia II, route des Dolines, a few hundreds meters further.